丁苯酞+依达拉奉治疗进展性脑梗死的临床效果

目的 探究丁苯酞+依达拉奉治疗进展性脑梗死(PCI)的临床效果.方法 102例PCI患者,以计算机抽号方式随机分为B组和A组,各51例.B组采用依达拉奉治疗,A组采用丁苯酞+依达拉奉联合治疗.比较两组临床效果、用药不良反应发生率、血液流变学指标、治疗前及治疗后1、2周的美国国立卫生研究院卒中量表(NIHSS)评分.结果...

The clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction

Objective To investigate the clinical effect of butylphthalide combined with edaravone in the treatment of progressive cerebral infarction(PCI).Methods A total of 102 PCI patients were randomly divided into group B and group A,with 51 cases in each group.Patients in group B were treated with edaravone,patients in group A were treated with butylphthalide and edaravone.The clinical effects,incidence of adverse drug reactions,hemorheological indexes,National Institutes of Health stroke scale(NIHSS)scores before treatment and 1 and 2 weeks after treatment were compared between the two groups.Results The total effective rate of treatment 90.20%in group A was higher than 68.63%in group B,and the difference was statistically significant(P<0.05).The incidence of adverse drug reactions in group A was 9.80%(5/51),which was not statistically significant compared with 7.84%(4/51)in group B(P>0.05).The fibrinogen,whole blood viscosity,and platelet aggregation rate of group A were(2.72±1.08)g/L,(1.02±0.02)mPa·s,and(52.33±7.54)%,which were lower than(3.35±1.11)g/L,(1.18±0.08)mPa·s,and(63.65±6.67)%of group B,and the difference was statistically significant(P<0.05).1 and 2 weeks after treatment,the NIHSS scores of group A were lower than those of group B,and the difference was statistically significant(P<0.05).Conclusion Butylphthalide combined with edaravone has significant clinical effect on patients with PCI,which can reduce the neurological damage,improve hemorheological indexes,greatly promote rehabilitation,and has less adverse reactions and high safety,which is worthy of clinical promotion and application.